XML 73 R50.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Collaboration and Other Agreements, Janssen Biotech, Inc. (Details) - Janssen Biotech Inc. - USD ($) $ / shares in Units, $ in Millions | 1 Months Ended | 12 Months Ended |
--- | --- | --- | ---
Jul. 31, 2016 | Jan. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | Jul. 31, 2015
Janssen MGD011 Agreement |  |  |  |  |  |  |
Collaboration and Other Agreements [Line Items] |  |  |  |  |  |  |
Sale of common stock (in shares) |  |  | 1,923,077 |  |  |  |
Proceeds of stock sale |  | $ 75.0 | $ 75.0 |  |  |  |
Non-refundable upfront payment |  |  |  |  |  | $ 50.0 |
Sale of common stock (in dollars per share) |  | $ 39.00 |  |  |  |  |
Premium received on stock purchase |  | $ 12.3 |  |  |  |  |
Total consideration |  | 125.0 |  |  |  |  |
Amount allocated to equity |  | 62.7 |  |  |  |  |
Amount allocated to license and R&D |  | $ 62.3 |  |  |  |  |
Clinical milestone earned during period |  |  |  |  |  |  | $ 10.0
Recognized revenue under agreement |  |  |  | $ 0.0 | $ 2.0 | $ 72.3 |
Janssen MGD015 Agreement |  |  |  |  |  |  |
Collaboration and Other Agreements [Line Items] |  |  |  |  |  |  |
Non-refundable upfront payment | $ 75.0 |  |  |  | 75.0 |  |
Recognized revenue under agreement |  |  |  | $ 0.6 | $ 75.8 |  |

X
- Definition Portion of consideration allocated to equity. + References No definition available. + Details
Name: | mgnx_AmountAllocatedToEquity
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Portion of consideration allocated to license and pre-clinical research and development. + References No definition available. + Details
Name: | mgnx_AmountAllocatedToLicenseAndRD
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Clinical milestone earned during the period + References No definition available. + Details
Name: | mgnx_ClinicalMilestoneEarnedDuringPeriod
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Initial fee received from collaboration or license agreement. + References No definition available. + Details
Name: | mgnx_NonRefundableUpfrontFees
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount by which purchase price exceeds fair value for common stock purchased by collaborator. + References No definition available. + Details
Name: | mgnx_PremiumReceivedOnStockPurchase
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Total consideration received under agreement. + References No definition available. + Details
Name: | mgnx_TotalConsideration
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_LicensesRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Cash received on stock transaction after deduction of issuance costs. + References No definition available. + Details
Name: | us-gaap_SaleOfStockConsiderationReceivedOnTransaction
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + References No definition available. + Details
Name: | us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + References No definition available. + Details
Name: | us-gaap_SaleOfStockPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_JanssenMGD011AgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_JanssenMGD015AgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |